recombinant human erythropoietin + recombinant human erythropoietin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy Induced Anemia
Conditions
Chemotherapy Induced Anemia
Trial Timeline
Feb 1, 2004 → May 1, 2005
NCT ID
NCT00144495About recombinant human erythropoietin + recombinant human erythropoietin
recombinant human erythropoietin + recombinant human erythropoietin is a phase 3 stage product being developed by Chugai Pharmaceutical for Chemotherapy Induced Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00144495. Target conditions include Chemotherapy Induced Anemia.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy Induced Anemia were approved
Approved (3) Terminated (4) Active (14)
🔄recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00144495 | Phase 3 | Completed |
Competing Products
20 competing products in Chemotherapy Induced Anemia